General News Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up EN FR March 5, 2024
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas EN NL March 4, 2024
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL February 29, 2024
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL February 23, 2024
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas EN NL February 15, 2024
General News Oxurion Receives EUR 850,000 in the framework of the Atlas Funding Program Eight and ninth tranches fully issued and paid-up EN FR February 14, 2024
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL February 9, 2024
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas EN NL February 7, 2024
General News Oxurion Announces New Strategic Orientation to De-risk and Diversify EN NL FR January 22, 2024
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas EN NL January 19, 2024
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL January 17, 2024
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL January 12, 2024
General News Regulated Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas EN NL December 28, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Negma Group EN NL December 6, 2023
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL December 1, 2023
News Regulated Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN NL November 20, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas EN NL November 19, 2023
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas EN NL November 16, 2023
General News Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year EN November 16, 2023
